Private Market View

Bright Peak Therapeutics

Drug Discovery · Allschwil, Switzerland · Founded 2017 · Privately Held (backing)

PA Mark · $/share
$1
Sep 2026
Implied valuation
Total raised
$244.0M
Last round
Later Stage VC (Series C)
Jun 2024

Key facts

as of Sep 2026
  • It has raised $244.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($90.0M) in Jun 2024.
  • Notable investors include Fidelity Management & Research Company, RA Capital Management, KB Investment, Alexandria Venture Investments, BlackRock12 tracked in total.
  • 2 institutional filers report fund marks on Bright Peak Therapeutics across 30 filings.
  • Bright Peak Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Jun 2024 ($90.0M sold to 21 investors).
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$1per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 2 inputs:N-PORT marks 100%
Free account
See the evidence behind this price
  • ·Post-money valuations for all 2 rounds
  • ·The complete investor list — 12 names
  • ·Watchlist + deal alerts for Bright Peak Therapeutics
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Bright Peak Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

2 filers · latest Apr 2026

2 SEC-registered funds reported 30 fair-value marks on Bright Peak Therapeutics between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.

Funding rounds

2 rounds
Jun 2024Later Stage VC (Series C)$90.0M
Jun 2021Early Stage VC (Series B)$107.0M

About Bright Peak Therapeutics

Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops immuno-cytokines with pharmacological properties that allow tissue and cell-specific targeting through cytokine payload with the added potential for enhanced efficacy, enabling doctors to improve treatment outcomes and quality of life for patients.

Industry
Drug Discovery
Sector
Healthcare
HQ
Allschwil, Switzerland
Founded
2017
Employees
57
Ownership
Privately Held (backing)